Financial Results for the Second Quarter of Fiscal Year Ending March 31, 2026 (FY2025)

from the beginning

Financial Results for the Second Quarter of Fiscal Year Ending March 31, 2026 (FY2025)

• Forward-Looking Statements and Use of Document

• Highlights

• P&L, FCF

• OP Variance Analysis (Q2):Growth due to strong sales

• OP Variance Analysis (Q2 YTD):Contribution from pricing measures and strong sales

• C&V: TIS led the way, continued expansion mainly in North America

• TMCS:Increased sales in PS contributed to revenue and profit growth

• TBCT:Plasma innovation drove revenue, profit progressed as planned

• Revenue by Region: Americas strongly drove overall growth

Revision of FY25 Guidance

• Assumptions for Guidance Revision

• Revision of FY25 Guidance

• Revision of FY25 Guidance (by Company)

• Key Points of the Revision of Adjusted Operating Profit

• Main Breakdown of Adjustment Items of Adjusted Operating Profit

• Toward Achieving GS26 and Beyond

References

• P&L (QoQ)

• SG&A (QoQ)

• SG&A (YoY)

• Adjusted Operating Profit: Adjustments

• Main Expenses Affecting AOP and OP (FY25 Guidance)

• CAPEX, Depreciation and Amortization, R&D Expenses

• Free Cash Flow

• Cash Flow (Q2)

• Cash Flow (Q2 YTD)

• Foreign Exchange Sensitivity

@

TIS Growth Roadmap ～Advancing Terumo’s Core Business through the Launch of DSS～

• Forward-Looking Statements and Use of Document

• Terumo Interventional Systems (TIS) Sales Trends and Breakdown

• TIS Growth Roadmap Highlights

• Key Strengths of TIS

• Access Growth Opportunities will Continue to Expand

• Established Track Record as a Category Leader in TLA Market

• Accelerating Growth through Product & Regional Expansion

• Overview of the Imaging Market

• Terumo’s Imaging Establishes a Powerful Presence in Japan

• Current Practice Requires Choosing Either IVUS or OFDI When Using Imaging Device

• DSS (Dual Sensor System) Solution

• Sales Outlook

• Future of TIS

OrganOx Updates After Closing

• Continue Rapid Revenue Growth

• Liver Transplantation is Expanding with the Adoption of Normothermic Machine Perfusion (NMP)

• Expanding Market Share with Flexible, Unique Solutions

• Combining Technologies to Accelerate Innovation

@